Brussels, Sept 16 2020. The latest investment is a Series-C financing by which existing shareholders and new investors have agreed to invest EUR 50 million. This investment will contribute to finance Univercells’ vaccines (including Covid-19 related projects), biosimilars and contract development and manufacturing business units.
Earlier in the year, Univercells created a joint venture and received equity investment by Gamma Biosciences, a KKR fund, in Univercells Technologies to further accelerate the development of the manufacturing technologies business of Univercells.
These deals constitute a significant milestone for this promising Belgian company, which continues to attract large international investors, such as the Bill & Melinda Gates Foundation, private equity fund KKR, and Belgian public investors, such as SFPI-FPIM and SRIW. This second investment round places Univercells at the top of the chart of Belgian life sciences companies being funded by high profile investors.
Univercells aligns its business model with SDGs 3, 8, 9 and 17. The company is held accountable to the goals through their dedicated Sustainability Committee, which oversees their impact plan and provides guidance on environmental and social issues for each business unit. In addition to KPIs around the number of doses of vaccines produced and technologies sold, Univercells is also tracking non-profit and academic partnerships, environmental accreditations such as GMP, and number of jobs created in LMICs, among others.
Please see press release:
- L'Echo: Hugues Bultot, CEO d'Univercells: "Le Covid a accéléré nos plans de développement" 10 Oct 2020
- Trends-tendances: "Coup d'accélerateur pour Univercells" 2 Nov 2020